A phase II trial of sitravatinib plus nivolumab after progression on prior immune checkpoint inhibitor (ICI) in patients with metastatic clear cell renal cell carcinoma (ccRCC)

被引：0
|
作者：
Dizman, Nazli
Adra, Nabil
Vaishampayan, Ulka N.
Xiao, Lianchun
Yuan, Ying
Campbell, Matthew T.
Gao, Jianjun
Zurita, Amado J.
Jonasch, Eric
Tannir, Nizar M.
Shah, Amishi Yogesh
Msaouel, Pavlos
Hahn, Andrew Warren
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Indiana Univ, Simon Comprehens Canc Ctr, Indianapolis, IN USA
[3] Univ Michigan, Div Hematol Oncol, Ann Arbor, MI USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Div Canc Med, Houston, TX USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4542
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma
    Molina, Ana M.
    Feldman, Darren R.
    Ginsberg, Michelle S.
    Kroog, Glenn
    Tickoo, Satish K.
    Jia, Xiaoyu
    Georges, Murielle
    Patil, Sujata
    Baum, Michael S.
    Reuter, Victor E.
    Motzer, Robert J.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (01) : 335 - 340
  • [22] Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
    Motzer, Robert J.
    Rini, Brian I.
    McDermott, David F.
    Redman, Bruce G.
    Kuzel, Timothy M.
    Harrison, Michael R.
    Vaishampayan, Ulka N.
    Drabkin, Harry A.
    George, Saby
    Logan, Theodore F.
    Margolin, Kim A.
    Plimack, Elizabeth R.
    Lambert, Alexandre M.
    Waxman, Ian M.
    Hammers, Hans J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (13) : 1430 - 1437
  • [23] Phase I/IB trial of sitravatinib (Sitra) plus nivolumab (Nivo) plus ipilimumab (Ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC) or other solid malignancies.
    Msaouel, Pavlos
    Gao, Jianjun
    Yuan, Ying
    Siefker-Radtke, Arlene O.
    Jonasch, Eric
    Goswami, Sangeeta
    Zurita, Amado J.
    Campbell, Matthew T.
    Shah, Amishi Yogesh
    Corn, Paul G.
    Ramos, Claudia
    Yan, Xiaohong
    Chin, Curtis
    Der-Torossian, Hirak
    Tannir, Nizar M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [24] Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma
    McGregor, Bradley A.
    Lalani, Aly-Khan A.
    Xie, Wanling
    Steinharter, John A.
    Bakouny, Ziad E.
    Martini, Dylan J.
    Fleischer, Justin H.
    Abou-Alaiwi, Sarah
    Nassar, Amin
    Nuzzo, Pier V.
    Kaymakcalan, Marina D.
    Braun, David A.
    Wei, Xiao X.
    Harshman, Lauren C.
    Bilen, Mehmet A.
    Choueiri, Toni K.
    EUROPEAN JOURNAL OF CANCER, 2020, 135 : 203 - 210
  • [25] Clinical and pathological outcomes of nephrectomy/metastasectomy in patients with metastatic renal cell carcinoma after prior immune checkpoint inhibitor exposure
    Amaral, Paulo Siqueira
    Beckermann, Katy
    Hillis, Mikala
    Schaffer, Kerry Roe
    Ancell, Kristin Kathleen
    Lambrecht, Morgan
    Kaiser, Elizabeth
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma
    Conduit, Ciara
    Davis, Ian D.
    Goh, Jeffrey C.
    Kichenadasse, Ganessan
    Gurney, Howard
    Harris, Carole A.
    Pook, David
    Krieger, Laurence
    Parnis, Francis
    Underhill, Craig
    Adams, Diana
    Roncolato, Felicia
    Joshua, Anthony
    Ferguson, Tom
    Prithviraj, Prashanth
    Morris, Michelle
    Harrison, Michelle
    Begbie, Stephen
    Hovey, Elizabeth
    George, Mathew
    Liow, Elizabeth C.
    Link, Emma K.
    McJannett, Margaret
    Gedye, Craig
    BJU INTERNATIONAL, 2024, 133 : 57 - 67
  • [27] Phase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis
    Lee, C-H.
    Shah, A. Y.
    Makker, V.
    Taylor, M. H.
    Shaffer, D.
    Hsieh, J. J.
    Cohn, A. L.
    DiSimone, C.
    Pinto Marin, A.
    Rasco, D. W.
    Ribe, S. G.
    Richards, D. A.
    Stepan, D. E.
    Dutcus, C. E.
    Wu, J.
    Schmidt, E. V.
    Perini, R. F.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2019, 30 : 483 - +
  • [28] Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial.
    Lee, Chung-Han
    Voss, Martin H.
    Carlo, Maria Isabel
    Chen, Ying-Bei
    Reznik, Eduard
    Knezevic, Andrea
    Lefkowitz, Robert A.
    Shapnik, Natalie
    Tassone, Diana
    Dadoun, Chloe
    Shah, Neil J.
    Owens, Colette Ngozi
    McHugh, Deaglan Joseph
    Aggen, David Henry
    Laccetti, Andrew Leonard
    Kotecha, Ritesh
    Feldman, Darren R.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non- Clear Cell Renal Cell Carcinoma
    Gupta, Ruby
    Ornstein, Moshe Chaim
    Li, Hong
    Allman, Kimberly D.
    Wood, Laura S.
    Gilligan, Timothy
    Garcia, Jorge A.
    Von Merveldt, Dendra
    Hammers, Hans J.
    Rini, Brian I.
    CLINICAL GENITOURINARY CANCER, 2020, 18 (06) : 429 - 435
  • [30] Fat Loss in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
    Lee, Ji Hyun
    Hwang, Soohyun
    Jee, ByulA
    Kim, Jae-Hun
    Lee, Jihwan
    Chung, Jae Hoon
    Song, Wan
    Sung, Hyun Hwan
    Jeon, Hwang Gyun
    Jeong, Byong Chang
    Seo, Seong Il
    Jeon, Seong Soo
    Lee, Hyun Moo
    Park, Se Hoon
    Kwon, Ghee Young
    Kang, Minyong
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (04)
12345